ECSP21073246A - Compuestos tricíclicos condensados útiles como agentes anticancerígenos - Google Patents
Compuestos tricíclicos condensados útiles como agentes anticancerígenosInfo
- Publication number
- ECSP21073246A ECSP21073246A ECSENADI202173246A ECDI202173246A ECSP21073246A EC SP21073246 A ECSP21073246 A EC SP21073246A EC SENADI202173246 A ECSENADI202173246 A EC SENADI202173246A EC DI202173246 A ECDI202173246 A EC DI202173246A EC SP21073246 A ECSP21073246 A EC SP21073246A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds useful
- anticancer agents
- tricyclic compounds
- condensed tricyclic
- condensed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La memoria descriptiva se refiere a compuestos de Fórmula (A) y sales farmacéuticamente aceptables de los mismos. La memoria descriptiva también se refiere a procesos e intermedios utilizados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962813885P | 2019-03-05 | 2019-03-05 | |
| US201962951146P | 2019-12-20 | 2019-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21073246A true ECSP21073246A (es) | 2021-11-30 |
Family
ID=69740367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202173246A ECSP21073246A (es) | 2019-03-05 | 2021-10-01 | Compuestos tricíclicos condensados útiles como agentes anticancerígenos |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20220204527A1 (es) |
| EP (1) | EP3935060B1 (es) |
| JP (1) | JP7453989B2 (es) |
| KR (1) | KR20210135539A (es) |
| CN (1) | CN113508118B (es) |
| AU (1) | AU2020231045B2 (es) |
| BR (1) | BR112021017408A2 (es) |
| CA (1) | CA3131156A1 (es) |
| CL (1) | CL2021002296A1 (es) |
| CO (1) | CO2021012381A2 (es) |
| CR (1) | CR20210504A (es) |
| DO (1) | DOP2021000183A (es) |
| EC (1) | ECSP21073246A (es) |
| IL (1) | IL285761B1 (es) |
| JO (1) | JOP20210241A1 (es) |
| MA (1) | MA55198A (es) |
| MX (1) | MX2021010674A (es) |
| PE (1) | PE20220140A1 (es) |
| SG (1) | SG11202109451TA (es) |
| TW (1) | TW202100532A (es) |
| UY (1) | UY38602A (es) |
| WO (1) | WO2020178282A1 (es) |
| ZA (1) | ZA202106192B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932633B2 (en) | 2018-05-07 | 2024-03-19 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| WO2020085493A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 新規なインダゾール化合物又はその塩 |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP4021444A4 (en) | 2019-08-29 | 2023-01-04 | Mirati Therapeutics, Inc. | G12D KRAS INHIBITORS |
| CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
| JP7340100B2 (ja) | 2019-10-28 | 2023-09-06 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｋｒａｓ ｇ１２ｃ変異型の小分子阻害薬 |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN114828964B (zh) | 2019-12-11 | 2023-11-24 | 伊莱利利公司 | Kras g12c抑制剂 |
| CN115135315A (zh) | 2019-12-20 | 2022-09-30 | 米拉蒂治疗股份有限公司 | Sos1抑制剂 |
| TWI799871B (zh) * | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| BR112022025550A2 (pt) | 2020-06-18 | 2023-03-07 | Revolution Medicines Inc | Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CN114437107A (zh) * | 2020-11-06 | 2022-05-06 | 江苏先声药业有限公司 | 哌嗪类化合物及其应用 |
| CN114539286B (zh) * | 2020-11-24 | 2024-02-02 | 成都百裕制药股份有限公司 | 哌嗪衍生物及其在医药上的应用 |
| TW202235082A (zh) | 2020-12-04 | 2022-09-16 | 美商美國禮來大藥廠 | Ｋｒａｓ ｇ１２ｃ抑制劑 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN117083279A (zh) * | 2021-04-08 | 2023-11-17 | 基因泰克公司 | 氧氮杂䓬化合物及其在癌症治疗中的用途 |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| TW202322819A (zh) | 2021-10-22 | 2023-06-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮的四環化合物、其製備方法及其在醫藥上的應用 |
| TW202325298A (zh) * | 2021-11-01 | 2023-07-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮的四環化合物、其製備方法及其在醫藥上的應用 |
| CN118434422A (zh) | 2021-12-28 | 2024-08-02 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和rasg12c抑制剂的组合 |
| WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| WO2023196887A1 (en) | 2022-04-08 | 2023-10-12 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and aurora a inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090318412A1 (en) * | 2006-07-11 | 2009-12-24 | Takahiro Matsumoto | Tricyclic heterocyclic compound and use thereof |
| NO2714752T3 (es) * | 2014-05-08 | 2018-04-21 | ||
| GB201409624D0 (en) * | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| EP3621968A1 (en) | 2017-05-11 | 2020-03-18 | Astrazeneca AB | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
-
2020
- 2020-03-03 BR BR112021017408A patent/BR112021017408A2/pt unknown
- 2020-03-03 JO JOP/2021/0241A patent/JOP20210241A1/ar unknown
- 2020-03-03 MA MA055198A patent/MA55198A/fr unknown
- 2020-03-03 KR KR1020217031298A patent/KR20210135539A/ko active Search and Examination
- 2020-03-03 AU AU2020231045A patent/AU2020231045B2/en active Active
- 2020-03-03 JP JP2021552640A patent/JP7453989B2/ja active Active
- 2020-03-03 IL IL285761A patent/IL285761B1/en unknown
- 2020-03-03 PE PE2021001444A patent/PE20220140A1/es unknown
- 2020-03-03 CA CA3131156A patent/CA3131156A1/en active Pending
- 2020-03-03 MX MX2021010674A patent/MX2021010674A/es unknown
- 2020-03-03 SG SG11202109451TA patent/SG11202109451TA/en unknown
- 2020-03-03 WO PCT/EP2020/055551 patent/WO2020178282A1/en unknown
- 2020-03-03 CR CR20210504A patent/CR20210504A/es unknown
- 2020-03-03 US US17/436,137 patent/US20220204527A1/en active Pending
- 2020-03-03 EP EP20708488.0A patent/EP3935060B1/en active Active
- 2020-03-03 CN CN202080018236.1A patent/CN113508118B/zh active Active
- 2020-03-05 UY UY0001038602A patent/UY38602A/es unknown
- 2020-03-05 TW TW109107275A patent/TW202100532A/zh unknown
-
2021
- 2021-08-26 ZA ZA2021/06192A patent/ZA202106192B/en unknown
- 2021-09-01 DO DO2021000183A patent/DOP2021000183A/es unknown
- 2021-09-02 CL CL2021002296A patent/CL2021002296A1/es unknown
- 2021-09-22 CO CONC2021/0012381A patent/CO2021012381A2/es unknown
- 2021-10-01 EC ECSENADI202173246A patent/ECSP21073246A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021010674A (es) | 2021-09-28 |
| EP3935060C0 (en) | 2023-11-15 |
| EP3935060A1 (en) | 2022-01-12 |
| CR20210504A (es) | 2022-02-08 |
| IL285761A (en) | 2021-10-31 |
| MA55198A (fr) | 2022-01-12 |
| UY38602A (es) | 2020-09-30 |
| IL285761B1 (en) | 2024-08-01 |
| US20220204527A1 (en) | 2022-06-30 |
| JOP20210241A1 (ar) | 2023-01-30 |
| JP2022523981A (ja) | 2022-04-27 |
| DOP2021000183A (es) | 2021-09-30 |
| AU2020231045A1 (en) | 2021-10-28 |
| KR20210135539A (ko) | 2021-11-15 |
| ZA202106192B (en) | 2022-08-31 |
| BR112021017408A2 (pt) | 2022-01-18 |
| CO2021012381A2 (es) | 2021-10-20 |
| CA3131156A1 (en) | 2020-09-10 |
| JP7453989B2 (ja) | 2024-03-21 |
| CN113508118B (zh) | 2024-07-19 |
| EP3935060B1 (en) | 2023-11-15 |
| PE20220140A1 (es) | 2022-01-27 |
| WO2020178282A1 (en) | 2020-09-10 |
| SG11202109451TA (en) | 2021-09-29 |
| CL2021002296A1 (es) | 2022-04-29 |
| AU2020231045B2 (en) | 2023-03-16 |
| CN113508118A (zh) | 2021-10-15 |
| TW202100532A (zh) | 2021-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21073246A (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| NI202000078A (es) | Compuestos heteroaril tetracíclicos | |
| NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
| UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
| UY38070A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| DOP2012000310A (es) | Morfolinopirimidinas y su uso en terapia | |
| CO2019008941A2 (es) | Moduladores del receptor de estrógeno | |
| CL2022000201A1 (es) | Inhibidores tricíclicos de kars dependientes de akr1c3 | |
| CL2016003329A1 (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| ECSP24028270A (es) | Compuestos espirocíclicos | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| ECSP22049160A (es) | Derivados de bencimidazol | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| CL2021000184A1 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
| CL2017002605A1 (es) | Derivados de indol | |
| EA202192366A1 (ru) | Конденсированные трициклические соединения, применимые в качестве противораковых средств |